Table 1.
Demographic and clinical characteristics of immediately and delayed detectable PSA and undetectable PSA for 3348 patients who underwent radical prostatectomy at University of California, San Francisco.
| Patient Characteristics | Immediately detectable PSA < 6mo after RP N = 480 | Delayed Detectable PSA 6mo-10yr after RP N = 642 | Undetectable PSA within 10 yr after RP N = 2226 | p-value* |
|---|---|---|---|---|
| Age at diagnosis, mean (+/−SD) | 62.3 (6.7) | 61.8 (7.4) | 60.8 (7.1) | <0.01 |
| PSA at diagnosis, median (IQR) | 9.1 (6.2, 14.3) | 6.6 (5.0, 10.0) | 5.9 (4.6, 8.3) | <0.01 |
| Race/ethnicity, n (%) | ||||
| Native American | 1 (<1) | 4 (1) | 5 (<1) | 0.15 |
| Asian/Pacific Islander | 39 (9) | 41 (7) | 126 (6) | |
| African American/Blac | 20 (5) | 21 (3) | 65 (3) | |
| White | 373 (86) | 536 (89) | 1843 (90) | |
| Mixed | 2 (<1) | 0 (0) | 6 (<1) | |
| Missing | 45 | 40 | 181 | |
| Biopsy Gleason grade group (GG), n (%) | ||||
| GG1 | 56 (13) | 113 (18) | 897 (42) | <0.01 |
| GG2 | 79 (18) | 198 (32) | 678 (32) | |
| GG3 | 128 (29) | 158 (25) | 341 (16) | |
| GG4/5 | 184 (41) | 151 (24) | 227 (11) | |
| Missing | 33 | 22 | 83 | |
| Clinical T-stage, n (%) | ||||
| T1 | 110 (23) | 128 (20) | 658 (30) | <0.01 |
| T2 | 256 (54) | 422 (66) | 1421 (64) | |
| T3 | 107 (22) | 82 (13) | 131 (6) | |
| T4 | 4 (1) | 7 (1) | 1 (<1) | |
| Missing | 3 | 3 | 15 | |
| Clinical CAPRA, n (%) | ||||
| Low (0-2) | 42 (11) | 114 (20) | 805 (42) | <0.01 |
| Intermediate (3–5) | 139 (36) | 292 (52) | 909 (47) | |
| High (>=6) | 207 (53) | 155 (28) | 223 (12) | |
| Missing | 92 | 81 | 289 | |
| Pathologic Gleason Grade group (GG), n (%) | ||||
| GG1 | 20 (4) | 47 (7) | 531 (24) | <0.01 |
| GG2 | 110 (23) | 286 (45) | 1154 (52) | |
| GG3 | 173 (36) | 189 (29) | 356 (16) | |
| GG4/5 | 177 (37) | 120 (19) | 185 (8) | |
| Pathologic T-stage, n (%) | ||||
| T2 | 145 (30) | 321 (50) | 1656 (74) | <0.01 |
| T3 | 324 (68) | 317 (49) | 562 (25) | |
| T4 | 11 (2) | 4 (1) | 8 (0) | |
| Positive margins, n (%) | ||||
| No | 257 (54) | 459 (71) | 1861 (84) | <0.01 |
| Yes | 223 (46) | 183 (29) | 365 (16) | |
| Extracapsular extension, n (%) | ||||
| No | 157 (33) | 338 (53) | 1677 (75) | <0.01 |
| Yes | 323 (67) | 304 (47) | 549 (25) | |
| Seminal vesicle invasion, n (%) | ||||
| No | 322 (67) | 563 (88) | 2133 (96) | <0.01 |
| Yes | 158 (33) | 79 (12) | 93 (4) | |
| Pathologic N-stage, n (%) | ||||
| NX | 82 (17) | 221 (35) | 1247 (56) | <0.01 |
| N0 | 272 (57) | 391 (61) | 930 (42) | |
| N1 | 126 (26) | 28 (4) | 36 (2) | |
| Missing | 0 | 2 | 13 | |
| Decipher score at radical prostatectomy, n (%) | ||||
| No test | 320 (67) | 481 (75) | 2046 (92) | <0.01 |
| Low < =0.45 | 17 (4) | 44 (7) | 48 (2) | |
| Intermediate >0.45–0.6 | 24 (5) | 32 (5) | 44 (2) | |
| High >0.6 | 119 (25) | 85 (13) | 88 (4) | |
| Surgical CAPRA-S, n (%) | ||||
| Low (0–2) | 47 (10) | 199 (31) | 1326 (60) | <0.01 |
| Intermediate (3–5) | 178 (37) | 312 (49) | 750 (34) | |
| High (>=6) | 255 (53) | 131 (20) | 150 (7) | |
PSA prostate specific antigen, CAPRA UCSF Cancer of the Prostate Risk Assessment
P-value from Kruskal-Wallis test comparing median values or from Pearson chi-square test comparing categorical variables